Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery

@article{Wang2018DesignAI,
  title={Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery},
  author={Jonathan Wang and Christopher Poon and Deborah D. Chin and Sarah Milkowski and Vivian Lu and Kenneth R Hallows and Eun Ji Chung},
  journal={Nano Research},
  year={2018},
  volume={11},
  pages={5584-5595}
}
One in three Americans is at risk for developing chronic kidney disease (CKD) and end-stage renal disease (ESRD), leading to the need for dialysis or a kidney transplant. Small-molecule drugs have been proposed as therapies to manage kidney diseases, but high dosages are often required to achieve therapeutic efficacy, generating off-target side effects, some of which are lethal. To address these limitations, we developed a novel, kidney-targeting multimodal micelle (KM) system for drug delivery… 
The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles
TLDR
Insight is provided into the design of micelle carriers for kidney targeting and their potential for future therapeutic application by developing small, organic nanoparticles called peptide amphiphile micelles (PAM) that passage through the glomerular filtration barrier for kidney accumulation.
Recent advances in nanotechnology-based drug delivery systems for the kidney.
Transdermal Delivery of Kidney-Targeting Nanoparticles Using Dissolvable Microneedles
TLDR
The studies show potential of KNP/MN patches as a non-invasive, self-administrable platform to direct therapies to the kidneys and validate KNP’s targeting to folate receptors in vitro.
Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.
Targeted Drug Delivery Systems for Kidney Diseases
TLDR
The recent advances in nanotherapeutic devices designed for kidney targeted delivery have been reviewed and some have achieved significant treatment effectiveness and reduced systemic side effect in kidney disease animal models.
Nanoparticles exhibit greater accumulation in kidney glomeruli during experimental glomerular kidney disease
TLDR
The findings underscore the importance of understanding and leveraging kidney pathophysiology in engineering new, targeted drug carriers that accumulate more in diseased glomeruli to treat glomerular kidney disease.
...
...

References

SHOWING 1-10 OF 62 REFERENCES
Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells.
TLDR
The potential of (KKEEE)3K as a promising candidate for kidney-targeted drug delivery to proximal tubule cells is suggested.
Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.
TLDR
This review highlights key studies that have shown success in utilizing peptide- or antibody-based ligands in nanoparticles to target the glomerulus, podocytes, or renal tubule cells in the kidney.
Drug Conjugation Affects Pharmacokinetics and Specificity of Kidney-Targeted Peptide Carriers.
TLDR
The results revealed that drug conjugation dramatically affects the targeting specificity, in the worst case leading to a total loss of kidney specificity, Nevertheless, efficient drug transport was achieved with the novel kidney carrier (KKEEE)3K, even with a multiple-drug loading of α-lipoic acid after intraveous and intraperitoneal administration.
Targeting kidney mesangium by nanoparticles of defined size
TLDR
These data show that nanoparticles of ~75 ± 25-nm diameters target the mesangium of the kidney, and establish design criteria for constructing nanoparticle-based therapeutics for targeting diseases that involve the mesANGium ofThe kidney.
Kidney–targeted drug delivery systems
Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?
TLDR
Delivery of nano-sized agents into cancer tissue is problematic because it mostly relies on the enhanced permeability and retention (EPR) effect that depends on the leaky nature of the tumor vasculature and the prolonged circulation of nano,sized agents, allowing slow but uneven accumulation in the tumor bed.
Gadolinium-Functionalized Peptide Amphiphile Micelles for Multimodal Imaging of Atherosclerotic Lesions
TLDR
These studies demonstrate the successful synthesis, and the molecular imaging capabilities of two types of CREKA-Gd PAMs for atherosclerosis, and provide the groundwork for the detection of thrombosis via contrast-enhancing agents and concurrent therapeutic delivery for theranostic applications.
Fibrin-Targeting, Peptide Amphiphile Micelles as Contrast Agents for Molecular MRI
TLDR
This study provides proof-of-concept of CREKA-Gd PAMs as contrast agents for molecular MRI, and a facile strategy for incorporating contrast agents and bioactive molecules into nano carriers to develop safe, targeted diagnostic carriers for clinical application.
Clinical Pharmacokinetics of Metformin
TLDR
The effect of structural variants of OCTs and other cation transporters on the pharmacokinetics of metformin appears small and the subsequent effects on clinical response are limited, however, intersubject differences in the levels of expression of OCT1 and OCT3 in the liver are very large and may contribute more to the variations in the hepatic uptake and clinical effect of metforms.
...
...